



Taro Pharmaceuticals U.S.A., Inc.

Mike Kakta  
Director-Corporate Accounts- Rx Sales  
Taro Pharmaceuticals,U.S.A., Inc.  
main #914-345-9001 Ext.6558  
Taro Fax # 914-345-9369  
cell # 404-414-8618  
[michael.kakta@taro.com](mailto:michael.kakta@taro.com)

Established in 1950, Taro Pharmaceutical Industries Ltd. Is a research-based, international, specialty pharmaceutical company that develops, manufactures, and markets prescription and over-the-counter pharmaceutical products.

Taro entered the U.S. market in 1988, after establishing its Canadian subsidiary in 1984 and receiving approval of its first topical product in the United States.

The U.S. has become Taro's largest market, accounting for more than 80% of our global sales. Our proprietary and generic U.S. products are both prescription and over-the-counter (OTC) medications, sold in Taro label and private-label (store brand). They include topical dermatological prescription pharmaceuticals (creams, ointments, gels, etc.), a category in which Taro is an acknowledged leader, as well as a growing line of oral dose drugs (tablets and capsules) used primarily in cardiovascular and neurological disorders.

Taro's proprietary product portfolio includes the brands Ovide<sup>®</sup> (malathion) Lotion, 0.5%; Topicort<sup>®</sup> (Desoximetasone) Cream 0.25%, Gel 0.05%, Ointment 0.25% and LP Cream 0.05%; and Lustra<sup>®</sup>, Lustra-AF<sup>®</sup> and Lustra-Ultra<sup>®</sup> (4% hydroquinone) products.

Taro U.S.A. maintains its own distribution facilities so that our U.S. customers, which include the largest drugstore chains and wholesalers, are assured of a continuous supply of Taro products.

Taro has research, manufacturing and marketing operations in North America and Israel.

We invite you to visit our website [www.taro.com](http://www.taro.com) often – you'll find new products and new information all the time. If you have any question that is not answered on this site, please contact us.